IL99345A - 6- Or 7-(2-imino-imidazolidine) 1, 4-benzoxazines and pharmaceutical compositions comprising them - Google Patents

6- Or 7-(2-imino-imidazolidine) 1, 4-benzoxazines and pharmaceutical compositions comprising them

Info

Publication number
IL99345A
IL99345A IL9934591A IL9934591A IL99345A IL 99345 A IL99345 A IL 99345A IL 9934591 A IL9934591 A IL 9934591A IL 9934591 A IL9934591 A IL 9934591A IL 99345 A IL99345 A IL 99345A
Authority
IL
Israel
Prior art keywords
compound
carbons
lower alkyl
benzoxazine
dihydro
Prior art date
Application number
IL9934591A
Other languages
English (en)
Other versions
IL99345A0 (en
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IL99345A0 publication Critical patent/IL99345A0/xx
Publication of IL99345A publication Critical patent/IL99345A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Treating Waste Gases (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL9934591A 1990-09-12 1991-08-29 6- Or 7-(2-imino-imidazolidine) 1, 4-benzoxazines and pharmaceutical compositions comprising them IL99345A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/582,034 US5091528A (en) 1990-09-12 1990-09-12 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents

Publications (2)

Publication Number Publication Date
IL99345A0 IL99345A0 (en) 1992-07-15
IL99345A true IL99345A (en) 1998-08-16

Family

ID=24327570

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9934591A IL99345A (en) 1990-09-12 1991-08-29 6- Or 7-(2-imino-imidazolidine) 1, 4-benzoxazines and pharmaceutical compositions comprising them

Country Status (17)

Country Link
US (1) US5091528A (fi)
EP (1) EP0548254B1 (fi)
JP (1) JP3096475B2 (fi)
AT (1) ATE180782T1 (fi)
AU (1) AU646098B2 (fi)
CA (1) CA2091440C (fi)
DE (1) DE69131295T2 (fi)
ES (1) ES2132093T3 (fi)
FI (1) FI94864C (fi)
HU (1) HU220671B1 (fi)
IE (1) IE913202A1 (fi)
IL (1) IL99345A (fi)
NO (1) NO303577B1 (fi)
NZ (1) NZ239580A (fi)
PT (1) PT98959B (fi)
WO (1) WO1992004345A1 (fi)
ZA (1) ZA917218B (fi)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5252595A (en) * 1990-02-28 1993-10-12 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5716952A (en) * 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US6077839A (en) * 1992-03-19 2000-06-20 Allergan Sales, Inc. Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists
US5369127A (en) * 1993-04-21 1994-11-29 Allergan, Inc. 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
US5710288A (en) * 1993-04-21 1998-01-20 Allergan 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
US5663189A (en) * 1993-07-01 1997-09-02 The Procter & Gamble Company 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
US5580892A (en) * 1993-10-22 1996-12-03 Allergan Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
JPH09506622A (ja) * 1993-12-17 1997-06-30 ザ、プロクター、エンド、ギャンブル、カンパニー α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノキサリン化合物
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
US5578607A (en) * 1993-12-17 1996-11-26 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
CA2179264C (en) * 1993-12-17 1999-05-18 Thomas Lee Cupps 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
CA2181909C (en) * 1994-01-24 2008-10-07 Stephen A. Munk Aromatic 2-amino-imidazole derivatives as alpha-2a adrenoceptor agonists
WO1995034302A2 (en) * 1994-06-16 1995-12-21 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
WO1996001813A1 (en) * 1994-07-11 1996-01-25 Allergan CONFORMATIONALLY RIGID BICYCLIC AND ADAMANTANE DERIVATIVES USEFUL AS α2-ADRENERGIC BLOCKING AGENTS
US6150389A (en) 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents
WO1996004270A1 (en) 1994-08-04 1996-02-15 Synaptic Pharmaceutical Corporation Novel benzimidazole derivatives
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6087361A (en) * 1995-05-12 2000-07-11 Allergan Sales, Inc. Aryl-imidazolines and aryl-imidazoles useful as α-2 adrenergic agonists without cardiovascular side effects
AU744018B2 (en) * 1995-05-12 2002-02-14 Allergan, Inc. Aryl-imidazolines and aryl-imidazoles useful as alpha-2 adrenergic agonists without cardiovascular side effects
JPH11505224A (ja) * 1995-05-12 1999-05-18 アラーガン 心臓血管系副作用を伴わないα▲下２▼アドレナリン作動剤として有用なアリール−イミダゾリンおよびアリール−イミダゾール
US5914342A (en) * 1995-06-07 1999-06-22 The Procter & Gamble Company 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
US5916900A (en) 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US6350780B1 (en) 1995-07-28 2002-02-26 Allergan Sales, Inc. Methods and compositions for drug delivery
CZ180599A3 (cs) * 1996-11-25 1999-11-17 The Procter & Gamble Company 2-Imidazolinylaminoindolová sloučenina, farmaceutický prostředek ji obsahující a její použití
KR20000069131A (ko) 1996-11-25 2000-11-25 데이비드 엠 모이어 알파-2 아드레날린수용체 아고니스트로서 유용한 구아니디닐 헤테로사이클 화합물
US6306877B1 (en) * 1999-08-09 2001-10-23 The Procter & Gamble Co. Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
WO1998023612A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists
WO1998023611A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
US6172095B1 (en) 1996-11-25 2001-01-09 The Procter & Gamble Company Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
ID24081A (id) * 1997-04-15 2000-07-06 Procter & Gamble Senyawa-senyawa 5-(2-imidazolinilamino) benzimidazol yang berguna sebagai agonis-agonis alfa-2-adrenoseptor
WO1999026942A1 (en) 1997-11-24 1999-06-03 The Procter & Gamble Company 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
CA2330611A1 (en) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
DE60027443D1 (de) * 1999-08-27 2006-05-24 Ligand Pharm Inc Androgenrezeptor-modulatorverbindungen und verfahren
PE20010647A1 (es) 1999-09-14 2001-06-23 Lilly Co Eli Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado
US8858961B2 (en) * 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
WO2009023752A1 (en) * 2007-08-15 2009-02-19 Allergan, Inc. Adrenergic compounds
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
PL2398500T3 (pl) 2009-02-20 2019-09-30 2-Bbb Medicines B.V. System dostarczania leków na bazie glutationu
KR101741629B1 (ko) 2009-05-06 2017-05-31 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US9040532B2 (en) 2009-10-06 2015-05-26 Allergan, Inc. Alpha adrenergic receptor modulators
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636219A (en) * 1964-03-02 1972-01-18 Du Pont Anticholinergic compositions containing certain thiazolines or imidazolines
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4515800A (en) * 1981-11-20 1985-05-07 Icilio Cavero Method of lowering intraocular pressure using phenylimino-imidazoles
US4587257A (en) * 1984-12-14 1986-05-06 Alcon Laboratories, Inc. Control of ocular bleeding using clonidine derivatives

Also Published As

Publication number Publication date
ZA917218B (en) 1992-06-24
PT98959A (pt) 1992-07-31
AU646098B2 (en) 1994-02-10
AU8643691A (en) 1992-03-30
EP0548254A1 (en) 1993-06-30
FI94864B (fi) 1995-07-31
US5091528A (en) 1992-02-25
NO930898L (no) 1993-05-10
NZ239580A (en) 1994-02-25
CA2091440C (en) 2003-11-11
CA2091440A1 (en) 1992-03-13
JPH06501004A (ja) 1994-01-27
PT98959B (pt) 1999-02-26
HU220671B1 (hu) 2002-04-29
NO930898D0 (no) 1993-03-11
IL99345A0 (en) 1992-07-15
FI931095A0 (fi) 1993-03-11
DE69131295T2 (de) 2000-01-27
JP3096475B2 (ja) 2000-10-10
DE69131295D1 (de) 1999-07-08
EP0548254B1 (en) 1999-06-02
NO303577B1 (no) 1998-08-03
HU9300695D0 (en) 1993-06-28
HUT65587A (en) 1994-07-28
IE913202A1 (en) 1992-02-25
ES2132093T3 (es) 1999-08-16
WO1992004345A1 (en) 1992-03-19
FI94864C (fi) 1995-11-10
ATE180782T1 (de) 1999-06-15
FI931095A (fi) 1993-04-22

Similar Documents

Publication Publication Date Title
US5091528A (en) 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
EP0426390B1 (en) Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
EP0422878B1 (en) (2-Imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
EP0549594B1 (en) (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
EP0409435B1 (en) Heteroaryl piperazine antipsychotic agents
US5350747A (en) Heteroaryl piperazine antipsychotic agents
US5198442A (en) (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
JPH07503015A (ja) （２−イミダゾリン−２−イルアミノ）キノキサリン誘導体の使用方法
KR101069948B1 (ko) 녹내장 및 근시 치료용 벤조 [ｇ] 퀴놀린 유도체
JP2005519117A (ja) キノリン誘導体
IE83705B1 (en) 6- OR 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as alpha adrenergic agents
CZ2799A3 (cs) Deriváty benzo[g]chinolinu
IL97220A (en) (2-imidazolin-2-ylamino) tetrahydro-quinoxalines and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees